Abstract 1235
Background
Uveal Melanoma (UVM) is the most common ocular malignancy. Many mutations were identified in affected patients defining genetic predisposition syndromes. Previous studies discussed separately the incidence of single or second primary ocular melanomas. However, understanding the genetic background, and relation to other tumors requires further investigation for defining the UVM subgroups, their shared developmental and, hence, the targeting mechanisms.
Methods
We used Surveillance Epidemiology and End Results program of the National Cancer Institute, United States, to review patients diagnosed with UVM, either as single primary or combined with other malignancies, between 1973 and 2015. We have calculated standardized incidence ratios (SIR) and measured risk in the form of Observed/Expected ratios (O/E) and Hazard Ratios (HR).
Results
We have identified 7,386 patients diagnosed with single primary UVM, besides 646 with UVM followed by another malignancy and 437 patients diagnosed with a primary UVM after other malignancies. SIR of developing another malignancy following UVM was significant and increased most within the first 5 years following UVM following choroid uveal melanoma (1.198, 95%CI=1.056-1.353). The risk of developing melanomas of the skin, thyroid cancers, and kidney cancers, increased significantly within the first 5 years following UVM, with SIRs (3.763, 95%CI=2.539-5.372), (3.158, 95%CI=1.270-6.506), and (2.618, 95%CI=1.465-4.317), respectively. SIR of developing a second UVM following another malignancy was significant between the 5th and 10th years following the first cancer diagnosis (O/E=1.204, 95% CI = 1.007-1.428), where the increase of UVM risk was highest among patients with primary prostate cancer (1.404, 95%CI=1.024-1.878) or leukemia (2.915, 95%CI=1.070-6.345). Cox models did not show a significant difference between the overall survival of single UVM and second UVM, but females showed better overall survival outcomes. In addition, Ciliary body tumors, and dark-skinned people were associated with worse survival outcomes.
Conclusions
The three groups of uveal melanoma showed different behaviors that may represent diverse underlying developmental mechanisms.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3117 - A modified Edmonton Symptom Assessment Scale for assessing symptoms in one day chemotherapy clinic
Presenter: Anjuleta Kampitsi
Session: Poster Display session 3
Resources:
Abstract
6058 - Level of physical activity and nutritional status in cancer patients with fatigue: an exploratory cross-sectional study
Presenter: Patrick Jahn
Session: Poster Display session 3
Resources:
Abstract
1980 - Catheter related necrotizing fascitiis in haematological patients. Case report and implications for nursing
Presenter: Arianna Rosich Soteras
Session: Poster Display session 3
Resources:
Abstract
3984 - Everyday life with Long-term Chemotherapy Induced Peripheral Neuropathy among Patient in Adjuvant Treatment for Colorectal Cancer – a Multi Methods Study
Presenter: Marlene Jensen
Session: Poster Display session 3
Resources:
Abstract
2202 - Scalp cooler is effective in reducing chemotherapy-induced alopecia among breast cancer patients : a single institution experience
Presenter: Emilia Gianotti
Session: Poster Display session 3
Resources:
Abstract
5942 - Nursing management of fatigue in cancer patients: mixed methods study
Presenter: Angela Tolotti
Session: Poster Display session 3
Resources:
Abstract
2930 - Awareness of Nursing Students about the Warning Signs of Cancer
Presenter: Hatice Yakar
Session: Poster Display session 3
Resources:
Abstract
2978 - Assessment of quality of life in patients with cancer and diabetes 2 in Northern Greece.
Presenter: STYLIANI MICHALOPOULOU
Session: Poster Display session 3
Resources:
Abstract
3400 - Radiation dose variables related to the causes of skin toxicities in women with breast cancer: a study proposal
Presenter: EULALIA PUJOL
Session: Poster Display session 3
Resources:
Abstract
2156 - How should the symptoms be managed after breast cancer surgery? An example of mobile app
Presenter: AYDANUR AYDIN
Session: Poster Display session 3
Resources:
Abstract